iOnctura SA

iOnctura SA is a clinical-stage biopharmaceutical company headquartered in Geneva, Switzerland. The company describes its mission as developing "high impact, low disruption therapies that extend healthspan" by disrupting the dynamic interplay at the heart of the tumor-stroma-immune interface. Rather than pursuing conventional cytotoxic approaches, iOnctura focuses on first-in-class mechanisms intended to be more effective and less toxic, targeting neglected and hard-to-treat cancers where existing therapies often carry punishing side effects. The company's pipeline is built around small molecules. Its lead candidate, Roginolisib (IOA-244), is described as the first allosteric modulator of PI3Kδ, with a unique chemical structure and binding mode; allosteric modulation changes the 3D structure of a protein to affect its activity. PI3K signalling is among the most commonly dysregulated pathways in cancer, and PI3Kδ is one of four isoforms of the catalytic subunit of PI3K kinase. A second candidate, Cambritaxestat (IOA-289), is presented as the only autotaxin inhibitor currently in clinical development to treat cancer, distinctively inhibiting both the catalytic and chaperone activities of the enzyme; autotaxin generates and transports lysophosphatidic acid (LPA), a bioactive phospholipid implicated in cancer and other diseases. A third program, IOA-359, is a novel small molecule targeting the TGF-β pathway. iOnctura positions itself as a values-driven, collaborative organization with a culture emphasizing pioneering science, sustainability, agility and responsibility. Its stated purpose is "giving every cancer sufferer hope." The company is led by a co-founder and CEO, Catherine Pickering, supported by an executive team and a board, with operations spanning key geographies. It is privately held and backed by investors, and it operates from Geneva while engaging internationally in oncology drug development.

iOnctura SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland. Public information about the company is centered on its scientific platform and pipeline rather than a long corporate history. The company was co-founded by Catherine Pickering, who serves as Chief Executive Officer and leads its corporate operations across key geographies. iOnctura's scientific premise is that many difficult cancers are shaped by the tumor-stroma-immune interface, and that disrupting this dynamic interplay can yield therapies that are both more effective and less toxic than conventional treatments. The company states that it interrogates first-in-class mechanisms and targets neglected and hard-to-treat cancers, where standard therapies often produce side effects that can be as punishing as the disease itself. Its pipeline has been built around small molecules. Roginolisib (IOA-244) is described as the first allosteric modulator of PI3Kδ, with a unique chemical structure and binding mode; allosteric modulation changes the three-dimensional structure of a protein to affect its activity. The phosphatidylinositol 3-kinase (PI3K) signalling pathway is one of the most commonly dysregulated pathways in cancer, and PI3Kδ is one of four isoforms of the catalytic subunit of PI3K kinase. While PI3Kδ expression is normally restricted to immune cells such as regulatory T cells and myeloid-derived suppressive cells, some cancers express high levels of PI3Kδ, which promotes tumor growth and survival. A second candidate, Cambritaxestat (IOA-289), is presented as the only autotaxin inhibitor currently in clinical development to treat cancer, and it distinctively inhibits both the catalytic and chaperone activities of the enzyme. Autotaxin (ATX) is an extracellular enzyme that generates and transports lysophosphatidic acid (LPA), a bioactive phospholipid that stimulates the proliferation, migration and survival of many cell types and has been implicated in a wide range of diseases, including cancer. A third program, IOA-359, is a novel small molecule targeting the TGF-β pathway. The company describes itself as values-driven, with a culture built on pioneering, sustainability, agility and responsibility, and a purpose of giving every cancer sufferer hope. It is privately held and supported by investors, and it operates from Geneva while engaging internationally in oncology drug development.

Clinical-stage oncology company developing first-in-class, less toxic small molecules targeting the tumor-stroma-immune interface for neglected and hard-to-treat cancers.

• Roginolisib (IOA-244)

  The first allosteric modulator of PI3Kδ, with a unique chemical structure and binding mode; allosteric modulation changes the 3D structure of a protein thereby affecting its activity.

• Cambritaxestat (IOA-289)

  The only autotaxin inhibitor currently in clinical development to treat cancer; distinctively inhibits both the catalytic and the chaperone activities of the enzyme.

• IOA-359

  A novel small molecule targeting the TGF-β pathway.

1. 1Home • iOncturaionctura.com
2. 2About • iOncturaionctura.com
3. 3iOnctura SA (Switzerland) - Wikidatawikidata.org